Article Sidebar

PDF (Tiếng Việt)
Published: 2025-10-31
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v195i10.4142
Issue
Vol. 195 No. 10 (2025)
Section
Các bài báo
How to Cite
Thảo, N. T. N., Tâm, P. T., Thuý, N. T., & Anh, L. N. (2025). 1. MMP-3 (-1171 5A/6A) gene polymorphism and risk of preeclampsia. Journal of Medical Research, 195(10), 1-11. https://doi.org/10.52852/tcncyh.v195i10.4142

1. MMP-3 (-1171 5A/6A) gene polymorphism and risk of preeclampsia

Nguyen Thi Ngoc Thao, Pham Thi Tam, Nguyen Thanh Thuy, Le Ngoc Anh

Main Article Content

Abstract

Preeclampsia (PE) is a serious pregnancy-related disorder associated with abnormal placental development. Matrix Metalloproteinase-3 (MMP-3) plays a critical role in trophoblast invasion and spiral artery remodeling. The MMP-3 (-1171 5A/6A) gene polymorphism may influence gene expression and has been implicated in PE susceptibility. This case-control study, conducted on 70 PE patients and 72 normotensive pregnant women at Hanoi Obstetrics and Gynecology Hospital, aimed to investigate the association between the MMP-3 (-1171 5A/6A) gene polymorphism and the risk of preeclampsia among Vietnamese pregnant women. Genotyping of the MMP-3 polymorphism was performed using the PCR-RFLP technique. The results showed that the genotype frequencies of 5A/5A, 5A/6A, and 6A/6A were 0%, 38.6%, and 61.4% in the PE group, and 0%, 15.3%, and 84.7% in the control group, respectively. Pregnant women with the 5A/6A genotype had a significantly increased risk of PE (OR = 3.5; 95% CI: 1.6 - 7.8; p = 0.002), particularly for late-onset PE (OR = 4.5; 95% CI: 1.9 - 11.1; p = 0.001). In conclusion, the MMP-3 (-1171 5A/6A) polymorphism may represent a genetic risk factor for preeclampsia, especially in cases of late-onset disease. These findings contribute to a better understanding of the genetic basis of PE.

Article Details

Keywords

Keywords: Preeclampsia, Matrix Metalloproteinase (MMP), MMP-3 polymorphism

References

1. Portelli M, Baron B. Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns. J Pregnancy. 2018; 2018: 2632637. doi:10.1155/2018/2632637.
2. Laura A. Magee, M.D., Kypros H. Nicolaides, M.D., and Peter von Dadelszen, D.Phil. Preeclampsia | N Engl J Med 2022; 386: 1817-1832. DOI: 10.1056/NEJMra2109523.
3. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond). 2006; 110(4): 443-458. doi:10.1042/CS20050323.
4. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019; 124(7): 1094-1112. doi:10.1161/CIRCRESAHA.118.313276.
5. Alicja Krejner, Malgorzata Litwiniuk & Tomasz Grzela (2016) Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives, Chronic Wound Care Management and Research, 3:, 29-39, DOI: 10.2147/CWCMR.S73819.
6. Sakowicz A, Lisowska M, Biesiada L, et al. Association of Maternal and Fetal Single-Nucleotide Polymorphisms in Metalloproteinase (MMP1, MMP2, MMP3, and MMP9) Genes with Preeclampsia. Disease Markers. 2018; 2018:e1371425. doi:10.1155/2018/1371425.
7. Coolman M, de Maat M, Van Heerde WL, et al. Matrix metalloproteinase-9 gene -1562C/T polymorphism mitigates preeclampsia. Placenta. 2007; 28(7): 709-713. doi:10.1016/j.placenta.2006.06.017.
8. Bộ Y tế. Hướng dẫn sàng lọc và điều trị dự phòng tiền sản giật. 2021.
9. Behforouz A, Dastgheib SA, Abbasi H, et al. Association of MMP-2, MMP-3, and MMP-9 Polymorphisms with Susceptibility to Recurrent Pregnancy Loss. Fetal Pediatr Pathol. 2021; 40(5): 378-386. doi:10.1080/15513815.2019.1710879.
10. Chen J, Khalil RA. Chapter Four - Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. In: Khalil RA, ed. Progress in Molecular Biology and Translational Science. Vol 148. Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy. Academic Press; 2017: 87-165. doi:10.1016/bs.pmbts.2017.04.001.
11. Laskowska M. Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia. BioMed Research International. 2017; 2017: e6432426. doi:10.1155/2017/6432426.
12. Lockwood CJ, Basar M, Kayisli UA, et al. Interferon-γ Protects First-Trimester Decidual Cells against Aberrant Matrix Metalloproteinases 1, 3, and 9 Expression in Preeclampsia. The American Journal of Pathology. 2014; 184(9): 2549-2559. doi:10.1016/j.ajpath.2014.05.025.
13. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology. 2000; 19(7): 623-629. doi:10.1016/S0945-053X(00)00102-5.
14. Dimitriadis, E., Rolnik, D.L., Zhou, W. et al. Pre-eclampsia. Nat Rev Dis Primers 9, 8 (2023). https://doi.org/10.1038/s41572-023-00417-6.